Large Scale Biology Corporation in Agreement With Schering-Plough Animal Health on Animal Vaccines
Tuesday October 28, 7:01 am ET
VACAVILLE, Calif.--(BUSINESS WIRE)--Oct. 28, 2003--Large Scale Biology Corporation (Nasdaq:LSBC - News) today announced an exclusive collaborative agreement with Schering-Plough Animal Health Corporation (SPAH), the worldwide animal health care business of Schering-Plough Corporation, to evaluate several vaccines for control of viral infections in animals.
Under the terms of the agreement, Large Scale Biology Corporation (LSBC) will produce trial quantities of vaccine antigens using its proprietary GENEWARE® biomanufacturing platform and SPAH will evaluate the vaccines for efficacy and safety in clinical models. The agreement includes a research program and, upon its successful completion, an option for a toll manufacturing agreement under which LSBC would manufacture and supply vaccine products for clinical trials and commercialization by SPAH. Financial details of the agreement were not disclosed.
LSBC's GENEWARE® biomanufacturing platform technology provides a method for producing animal health vaccines using non-GMO (genetically modified organisms) non-food plants as a production host.
"We welcome this relationship with SPAH, a world leader in animal health," said Kevin J. Ryan, President and CEO of LSBC. "This collaboration is expected to provide additional validation for our unique biomanufacturing technology, creating solid product development and manufacturing opportunities."
"Schering-Plough has broad experience and proven expertise in applying new technologies in the development of animal health products," said Dr. K.J. Varma, Vice President, Research and Development, Schering-Plough Animal Health. "This collaboration with LSBC will explore new approaches to developing and manufacturing vaccines, further strengthening our position in the growing and important vaccine segment of the animal health business."
About Schering-Plough Animal Health
Schering-Plough Animal Health Corporation is the worldwide animal health care business of Schering-Plough Corporation (NYSE:SGP - News) of Kenilworth, N.J., a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.
About Large Scale Biology Corporation
Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs and vaccines for effective treatment of disease. Corporate offices, the Genomics Division and Biopharmaceutical Development laboratories are headquartered in Vacaville, California; the Company's Proteomics Division is located in Germantown, Maryland; and the Company's commercial-scale biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com. |
